DMII.US Drugs Made In America Acquisition II Corp. Ordinary Shares
- Market cap
- USD 652M
- P/E
- 34.1x
- P/B
- 1.32x
- ROE
- 3.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DMII.US undervalued?
Graham numberDMII.US trades 41.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Drugs Made In America Acquisition II Corp. Ordinary Shares fundamental analysis
No fundamental analysis for Drugs Made In America Acquisition II Corp. Ordinary Shares yet.
Drugs Made In America Acquisition II Corp. Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Full company profileDrugs Made In America Acquisition II Corp. Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Drugs Made In America Acquisition II Corp. Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | - | 0.00 | 0.00 |
| Operating Income | -152K | -1.30M | -489K |
| EBITDA | -152K | -1.30M | -489K |
| Net Income | -152K | 4.19M | 17.5M |
| EPS | 0.00 | 0.32 | 0.35 |
| Balance Sheet | |||
| Total Assets | 138K | 505M | 514M |
| Total Liabilities | 255K | 17.8M | 18.1M |
| Shareholders' Equity | -117K | 487M | 496M |
| Cash & Short-term Investments | 17.0K | 223.00 | 175K |
| Total Debt | 250K | - | 450K |
| Cash Flow | |||
| Operating Cash Flow | -194K | -1.02M | -550K |
| Capital Expenditure | 0.00 | 0.00 | 6.00 |
| Free Cash Flow | -194K | -1.02M | -550K |
| Ratios | |||
| ROE | - | 0.9% | 3.5% |
| ROA | -109.9% | 0.8% | 3.4% |
| Debt to Equity | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Drugs Made In America Acquisition II Corp. Ordinary Shares dividends
Drugs Made In America Acquisition II Corp. Ordinary Shares has not paid dividends in the last 2 fiscal years.
Who owns Drugs Made In America Acquisition II Corp. Ordinary Shares
- Insiders 15.27%
- Institutions 72.05%
- Public & others 12.68%
- Shares outstanding 63.7M
- Free float 54.0M
Top funds holding DMII.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| CrossingBridge Low Dur Hi Inc Instl | 1.07M | 1.69% | 0.00% | Sep 2026 |
| First Trust Merger Arbitrage Cl I | 913K | 1.43% | 0.00% | Jun 2026 |
| PICTON Arbitrage Plus Alternative Fund F | 685K | 1.08% | 0.00% | Jun 2026 |
| The Merger Fund A | 515K | 0.81% | +25.16% | Jun 2026 |
| GAMCO Intl SICAV Merger Arbtrg I (USD) | 129K | 0.20% | -17.73% | Jun 2026 |
| RiverNorth Opportunities | 100K | 0.16% | 0.00% | Jun 2026 |
| Pender Alternative Arbitrage Plus F | 68.8K | 0.11% | 0.00% | Sep 2026 |
| Accelerate Arbitrage ETF | 54.8K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 45.9K | 0.07% | 0.00% | Aug 2026 |
| PICTON Arbitrage Alternative Fund F | 42.7K | 0.07% | 0.00% | Jun 2026 |
| JNL Multi-Manager Alternative A | 37.3K | 0.06% | +29.08% | Sep 2026 |
| Virtus Westchester Event-Driven Fd I | 27.2K | 0.04% | +24.53% | Jun 2026 |
| Destinations Low Duration Fixed Inc I | 26.3K | 0.04% | 0.00% | Oct 2026 |
| Virtus Westchester Credit Event Fd I | 15.8K | 0.02% | 0.00% | Jun 2026 |
| Principal Global Multi-Strategy Instl | 14.2K | 0.02% | 0.00% | Sep 2026 |
| SPAC and New Issue ETF | 10.8K | 0.02% | 0.00% | Oct 2026 |
| Pender Alternative Arbitrage Cl FF | 10.7K | 0.02% | 0.00% | Aug 2026 |
| Robinson Opportunistic Income Instl | 10.0K | 0.02% | 0.00% | Sep 2026 |
| JNL/Westchester Capital Event Driven A | 9.88K | 0.02% | 0.00% | Sep 2026 |
| The Merger Fund VL I | 5.13K | 0.01% | +23.96% | Jun 2026 |
Top institutions holding DMII.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Karpus Management Inc | 2.79M | 4.38% | +7.32% | Jun 2026 |
| Mmcap International Inc. Spc | 2.70M | 4.24% | 0.00% | Jun 2026 |
| Magnetar Financial LLC | 2.70M | 4.24% | 0.00% | Jun 2026 |
| Glazer Capital, LLC | 2.34M | 3.68% | -0.28% | Jun 2026 |
| Highbridge Capital Management, LLC | 2.24M | 3.52% | +896.08% | Jun 2026 |
| Millennium Management LLC | 1.99M | 3.13% | +0.87% | Jun 2026 |
| Hudson Bay Capital Management LP | 1.97M | 3.09% | 0.00% | Jun 2026 |
| Wolverine Asset Management LLC | 1.86M | 2.91% | +3.34% | Jun 2026 |
| Polar Asset Management Partners | 1.50M | 2.35% | 0.00% | Jun 2026 |
| Tenor Capital Management Co Lp | 1.50M | 2.35% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 1.48M | 2.32% | +6.11% | Jun 2026 |
| Cnh Partners, LLC | 1.13M | 1.78% | +1.70% | Jun 2026 |
| Aristeia Capital, LLC | 1.10M | 1.73% | 0.00% | Jun 2026 |
| First Trust Capital Management L.P. | 1.07M | 1.68% | 0.00% | Jun 2026 |
| Davidson Kempner Capital Management LP | 1.00M | 1.57% | 0.00% | Jun 2026 |
| Omers Administration Corp | 1.00M | 1.57% | 0.00% | Jun 2026 |
| Picton Mahoney Asset Management | 888K | 1.39% | +1.49% | Jun 2026 |
| Two Sigma Investments LLC | 887K | 1.39% | 0.00% | Jun 2026 |
| Mercuria Capital Strategies, LLC | 750K | 1.18% | 0.00% | Jun 2026 |
| Moore Capital Management, LP | 750K | 1.18% | 0.00% | Jun 2026 |
Drugs Made In America Acquisition II Corp. Ordinary Shares company profile
- Company name
- Drugs Made In America Acquisition II Corp. Ordinary Shares
- Ticker
- DMII.US
- ISIN
- KYG2851K1040
- Exchange
- USA Stocks
- Listed since
- Dec 3, 2025
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- December
- Address
- 420 Lexington Avenue, New York, NY, United States, 10170
- Phone
- 917 982 4565
- Website
- -
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Drugs Made In America Acquisition II Corp. Ordinary Shares management
2- Mr. Roger BendelacChief Executive Officer · born 1957
- Mr. Saleem Elmasri CPACFO & Principal Accounting Officer · born 1986